NAS:EXAS (USA) Also trade in: Germany

Exact Sciences Corp

$ 116.58 0.88 (0.76%)
Volume: 177,049 Avg Vol (1m): 1,748,510
Market Cap $: 15.17 Bil Enterprise Value $: 14.68 Bil
P/E (TTM): 0.00 P/B: 19.07
Earnings Power Value -42
Net Current Asset Value 3.28
Tangible Book 5.79
Projected FCF -6.1
Median P/S Value 193.62
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 5/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 1.61
Cash-To-Debt ranked higher than
66.67% of 261 companies
in the Diagnostics & Research industry.
Industry Max: 32990, Med: 3.52, Min: 0.01
EXAS: 1.61
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 1.61, Med: 5103.95, Max: 10000
Current: 1.61
1.61
10000
Equity-to-Asset 0.44
Equity-to-Asset ranked higher than
89.54% of 239 companies
in the Diagnostics & Research industry.
Industry Max: 0.97, Med: 0.61, Min: -2.81
EXAS: 0.44
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -0.41, Med: 0.72, Max: 0.96
Current: 0.44
-0.41
0.96
Debt-to-Equity 1.02
Debt-to-Equity ranked higher than
98.78% of 164 companies
in the Diagnostics & Research industry.
Industry Max: 22.86, Med: 0.36, Min: 0.01
EXAS: 1.02
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: 0.01, Med: 0.01, Max: 1.02
Current: 1.02
0.01
1.02
Debt-to-EBITDA -5.62
Debt-to-EBITDA ranked lower than
100.00% of 116 companies
in the Diagnostics & Research industry.
Industry Max: 77.72, Med: 1.77, Min: 0.03
EXAS: -5.62
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -5.98, Med: -0.04, Max: -0.01
Current: -5.62
-5.98
-0.01
Piotroski F-Score 4
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 8.50
DISTRESS
GREY
SAFE
Beneish M-Score -1.99
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -90.62%
WACC 16.24%

Profitability & Growth : 5/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -36.29
Operating Margin ranked lower than
65.70% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 53.36, Med: -0.59, Min: -70300
EXAS: -36.29
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -5587.93, Med: -312.12, Max: -35.09
Current: -36.29
-5587.93
-35.09
Net Margin % -41.58
Net Margin ranked lower than
64.73% of 241 companies
in the Diagnostics & Research industry.
Industry Max: 41.13, Med: -2.48, Min: -119600
EXAS: -41.58
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -5564.4, Med: -307.98, Max: -38.54
Current: -41.58
-5564.4
-38.54
ROE % -30.34
ROE ranked lower than
61.16% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 61.7, Med: -6.75, Min: -12038.19
EXAS: -30.34
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -498.66, Med: -43.47, Max: -26.74
Current: -30.34
-498.66
-26.74
ROA % -14.50
ROA ranked lower than
62.21% of 262 companies
in the Diagnostics & Research industry.
Industry Max: 1174.65, Med: -4.54, Min: -1248.4
EXAS: -14.5
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -57.65, Med: -39.75, Max: -14.5
Current: -14.5
-57.65
-14.5
ROC (Joel Greenblatt) % -84.68
ROC (Joel Greenblatt) ranked lower than
68.34% of 259 companies
in the Diagnostics & Research industry.
Industry Max: 17601.65, Med: -9.57, Min: -3842027.78
EXAS: -84.68
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -3464.42, Med: -639.65, Max: -84.68
Current: -84.68
-3464.42
-84.68
3-Year Total Revenue Growth Rate 125.90
3-Year Revenue Growth Rate ranked higher than
99.45% of 182 companies
in the Diagnostics & Research industry.
Industry Max: 371, Med: 4.8, Min: -100
EXAS: 105.6
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: -12.2, Max: 371
Current: 105.6
0
371
3-Year Total EBITDA Growth Rate 8.40
3-Year EBITDA Growth Rate ranked higher than
52.25% of 178 companies
in the Diagnostics & Research industry.
Industry Max: 141.7, Med: 10.1, Min: -340.1
EXAS: 16.7
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -46.2, Med: 11.25, Max: 39.4
Current: 16.7
-46.2
39.4
3-Year EPS w/o NRI Growth Rate 5.80
3-Year EPS w/o NRI Growth Rate ranked lower than
55.83% of 163 companies
in the Diagnostics & Research industry.
Industry Max: 138.7, Med: 10.1, Min: -301
EXAS: 5.8
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: -46.5, Med: 13.1, Max: 43.1
Current: 5.8
-46.5
43.1

» EXAS's 30-Y Financials

Financials (Next Earnings Date: 2019-08-01)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:EXAS

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Medical Diagnostics & Research » Diagnostics & Research    NAICS : 621511    SIC : 8731
Compare XTER:SRT NYSE:DGX SHSE:603259 NAS:DXCM NYSE:WAT TSE:6869 XPAR:BIM NYSE:PKI NYSE:BIO NYSE:QGEN NYSE:LH XPAR:ERF NAS:ICLR NYSE:MTD NAS:GH NAS:BRKR NYSE:CRL MIL:DIA NAS:PRAH NAS:SYNH
Traded in other countries EXK.Germany
Address 441 Charmany Drive, Madison, WI, USA, 53719
Exact Sciences is a molecular diagnostics company focused on the early detection and prevention of certain types of cancer. Its core product is a noninvasive screening test, Cologuard, which analyzes stool-based DNA samples to detect the precancerous and early stages of colorectal cancer. The test includes DNA markers and a protein marker that can detect blood in the stool. Exact Sciences receives revenue from two sources: laboratory services and licensing fees. Its laboratory services revenue is generated by diagnostic services that use the Cologuard test. Exact Sciences also receives revenue from the licensing of its product rights.

Ratios

Current vs industry vs history
PB Ratio 19.07
PB Ratio ranked lower than
85.31% of 245 companies
in the Diagnostics & Research industry.
Industry Max: 270, Med: 4.02, Min: 0.15
EXAS: 19.07
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 1.69, Med: 7.79, Max: 36.44
Current: 19.07
1.69
36.44
PS Ratio 27.61
PS Ratio ranked lower than
85.65% of 230 companies
in the Diagnostics & Research industry.
Industry Max: 6350, Med: 3.81, Min: 0.07
EXAS: 27.61
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 10.55, Med: 45.52, Max: 1325.45
Current: 27.61
10.55
1325.45
EV-to-EBIT -87.95
EV-to-EBIT ranked lower than
100.00% of 118 companies
in the Diagnostics & Research industry.
Industry Max: 341.21, Med: 25.06, Min: 5.74
EXAS: -87.95
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -87.2, Med: -14.55, Max: -0.4
Current: -87.95
-87.2
-0.4
EV-to-EBITDA -103.69
EV-to-EBITDA ranked lower than
100.00% of 132 companies
in the Diagnostics & Research industry.
Industry Max: 486.47, Med: 20.75, Min: 3.94
EXAS: -103.69
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -102.81, Med: -14.9, Max: -0.5
Current: -103.69
-102.81
-0.5
EV-to-Revenue 27.93
EV-to-Revenue ranked lower than
83.88% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 19679, Med: 4.24, Min: 0.09
EXAS: 27.93
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 4.3, Med: 37.2, Max: 1390.2
Current: 27.93
4.3
1390.2
Current Ratio 8.39
Current Ratio ranked higher than
86.80% of 250 companies
in the Diagnostics & Research industry.
Industry Max: 97.84, Med: 2.58, Min: 0.02
EXAS: 8.39
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 1.02, Med: 9.34, Max: 50.84
Current: 8.39
1.02
50.84
Quick Ratio 8.13
Quick Ratio ranked higher than
86.00% of 250 companies
in the Diagnostics & Research industry.
Industry Max: 97.84, Med: 2.14, Min: 0.02
EXAS: 8.13
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 1.02, Med: 9.34, Max: 50.84
Current: 8.13
1.02
50.84
Days Inventory 100.12
Days Inventory ranked higher than
55.39% of 204 companies
in the Diagnostics & Research industry.
Industry Max: 917.88, Med: 79.76, Min: 0.37
EXAS: 100.12
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 54.55, Med: 79.66, Max: 170.49
Current: 100.12
54.55
170.49
Days Sales Outstanding 38.91
Days Sales Outstanding ranked higher than
82.84% of 204 companies
in the Diagnostics & Research industry.
Industry Max: 521.64, Med: 67.51, Min: 1
EXAS: 38.91
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 31.32, Med: 36.25, Max: 279.33
Current: 38.91
31.32
279.33
Days Payable 46.29
Days Payable ranked higher than
58.82% of 187 companies
in the Diagnostics & Research industry.
Industry Max: 981.81, Med: 63.34, Min: 1
EXAS: 46.29
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 5.73, Med: 155.87, Max: 15634.17
Current: 46.29
5.73
15634.17

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -8.10
3-Year Share Buyback Rate ranked lower than
58.89% of 180 companies
in the Diagnostics & Research industry.
Industry Max: 3.4, Med: -7.9, Min: -1732.6
EXAS: -8.1
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -217.1, Med: -11.7, Max: -1
Current: -8.1
-217.1
-1

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 20.29
Price-to-Tangible-Book ranked lower than
74.40% of 207 companies
in the Diagnostics & Research industry.
Industry Max: 272.36, Med: 6.46, Min: 0.21
EXAS: 20.29
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 1.87, Med: 6.36, Max: 33.71
Current: 20.29
1.87
33.71
Price-to-Median-PS-Value 0.60
Price-to-Median-PS-Value ranked higher than
83.42% of 193 companies
in the Diagnostics & Research industry.
Industry Max: 7.22, Med: 1.01, Min: 0.01
EXAS: 0.6
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.24, Med: 0.94, Max: 185.2
Current: 0.6
0.24
185.2
Earnings Yield (Joel Greenblatt) % -1.15
Earnings Yield (Greenblatt) ranked lower than
52.08% of 265 companies
in the Diagnostics & Research industry.
Industry Max: 17.42, Med: -0.98, Min: -1428.57
EXAS: -1.15
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -275, Med: -6.9, Max: -1.16
Current: -1.15
-275
-1.16

More Statistics

Revenue (TTM) (Mil) $ 526.21
EPS (TTM) $ -1.77
Beta 2.38
Volatility % 57.62
52-Week Range $ 47.78 - 116.74
Shares Outstanding (Mil) 129.14

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 4
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy N